دورية أكاديمية
A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial
| العنوان: | A randomized, double-blind, active-controlled trial assessing the efficacy and safety of a fixed-dose combination (FDC) of MEtformin hydrochloride 1000 mg ER, SItagliptin phosphate 100 mg, and DApagliflozin propanediol 10 mg in Indian adults with type 2 diabetes: The MESIDA trial |
|---|---|
| المؤلفون: | Singh, Awadhesh Kumar, Sahay, Rakesh, Gil, Navneet, Tripathi, Sudhir, Khandelwal, Vipul, Basu, Indraneel, Shembalkar, Jayashree, Srivastava, Manoj Kumar, Bhatia, Girish, Pathak, Vaishali, Dange, Amol, Chaudhri, Mayura, Naskar, Arindam, Mondal, Ashish, Gangwal, Pawan, Kumar, Surendra, Kumar, Deepak, Raju, Yandrapati gnana sundara, Sorate, Sanket, Gavli, Onkar, Kumbalkar, Sunita, Varade, Deepak, Chaudhari, Harshal, Prasad, Durga, Patil, Manoj, Bhagwat, Nikhil, Agarwal, Rohit, Pandey, Arun, Ghosh, Soumya, Patil, Shubhashree, Kini, Vishal, Sharma, Akhilesh, Mayabhate, MayurAff32, IDs13410024013219_cor33, Pawar, Roshan, Rajput, Aashish, Shahavi, Vinakaya |
| المصدر: | International Journal of Diabetes in Developing Countries: Incorporating Diabetes Bulletin. 44(1):67-76 |
| قاعدة البيانات: | Springer Nature Journals |
Find this article in full text from Springer Verlag. 
Full Text Finder كن أول من يترك تعليقا!